tumor-infiltrating lymphocytes

[G1 Therapeutics, Inc.] G1 Therapeutics, Inc. announced that the company has initiated a Phase II, single arm, open-label study of trilaciclib in patients with early-stage triple negative breast cancer designed to further investigate the role of trilaciclib in modulating the anti-tumor immune response.

[Cellular Immunology] Researchers examined tumor-infiltrating lymphocytes in colorectal cancer expressing different levels of SIRT1.

[Journal of Clinical Investigation] Using barcoded pMHC multimers, scientists provided a comprehensive mapping of CD8+ T cells recognizing neoepitopes in Tumor-Infiltrating Lymphocyte infusion products and blood samples from 26 metastatic mela-noma patients who received adoptive cell therapy.

[Signal Transduction and Targeted Therapy] Fusobacterium nucleatum induces different immune responses in colorectal cancer (CRC) with different microsatellite-instability statuses. Scientists investigated the effect of F. nucleatum on anti-PD-L1 therapy in CRC.

[Cell Reports] Investigators showed that autotaxin (ATC) secreted by melanoma cells was chemorepulsive for tumor-infiltrating lymphocytes and circulating CD8+ T cells ex vivo, with autotaxin functioning as an LPA-producing chaperone.

[Journal of Biomedical Science] Scientists applied three colon cancer cell lines, including microsatellite stable cell lines, which are SW480 and SW620, and microsatellite instability-high cell line, which is DLD-1.